Joshua E. Allen, Ph.D. - Publications

Affiliations: 
2012 Biochemistry and Molecular Biophysics University of Pennsylvania, Philadelphia, PA, United States 
Area:
Oncology, Pharmacy

48 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2019 Nii T, Prabhu VV, Ruvolo V, Madhukar N, Zhao R, Mu H, Heese L, Nishida Y, Kojima K, Garnett MJ, McDermott U, Benes CH, Charter N, Deacon S, Elemento O, ... Allen JE, et al. Imipridone ONC212 activates orphan G protein-coupled receptor GPR132 and integrated stress response in acute myeloid leukemia. Leukemia. PMID 31127149 DOI: 10.1038/s41375-019-0491-z  0.6
2019 Stein MN, Malhotra J, Tarapore RS, Malhotra U, Silk AW, Chan N, Rodriguez L, Aisner J, Aiken RD, Mayer T, Haffty BG, Newman JH, Aspromonte SM, Bommareddy PK, Estupinian R, ... ... Allen JE, et al. Safety and enhanced immunostimulatory activity of the DRD2 antagonist ONC201 in advanced solid tumor patients with weekly oral administration. Journal For Immunotherapy of Cancer. 7: 136. PMID 31118108 DOI: 10.1186/s40425-019-0599-8  0.96
2018 Prabhu VV, Madhukar NS, Gilvary C, Kline CLB, Oster S, El-Deiry WS, Elemento O, Doherty FC, VanEngelenburg A, Durrant J, Tarapore RS, Deacon S, Charter N, Jung J, Park DM, ... ... Allen JE, et al. Dopamine Receptor D5 is a Modulator of Tumor Response to Dopamine Receptor D2 Antagonism. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 30559168 DOI: 10.1158/1078-0432.CCR-18-2572  0.96
2018 Ishida CT, Zhang Y, Bianchetti E, Shu C, Nguyen TT, Kleiner G, Sanchez-Quintero M, Quinzii CM, Westhoff MA, Karpel-Massler G, Prabhu VV, Allen JE, Siegelin MD. Metabolic Reprogramming by Dual AKT/ERK Inhibition Through Imipridones Elicits Unique Vulnerabilities in Glioblastoma. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 30037819 DOI: 10.1158/1078-0432.CCR-18-1040  0.6
2017 Kline CLB, Ralff MD, Lulla AR, Wagner JM, Abbosh PH, Dicker DT, Allen JE, El-Deiry WS. Role of Dopamine Receptors in the Anticancer Activity of ONC201. Neoplasia (New York, N.Y.). 20: 80-91. PMID 29216597 DOI: 10.1016/j.neo.2017.10.002  0.96
2017 Prabhu VV, Talekar MK, Lulla AR, Kline CLB, Zhou L, Hall J, Van den Heuvel APJ, Dicker DT, Babar J, Grupp SA, Garnett MJ, McDermott U, Benes CH, Pu JJ, Claxton DF, ... ... Allen JE, et al. Single agent and synergistic combinatorial efficacy of first-in-class small molecule imipridone ONC201 in hematological malignancies. Cell Cycle (Georgetown, Tex.). 1-29. PMID 29157092 DOI: 10.1080/15384101.2017.1403689  0.96
2017 Prabhu VV, Lulla AR, Madhukar NS, Ralff MD, Zhao D, Kline CLB, Van den Heuvel APJ, Lev A, Garnett MJ, McDermott U, Benes CH, Batchelor TT, Chi AS, Elemento O, Allen JE, et al. Cancer stem cell-related gene expression as a potential biomarker of response for first-in-class imipridone ONC201 in solid tumors. Plos One. 12: e0180541. PMID 28767654 DOI: 10.1371/journal.pone.0180541  0.96
2017 Wagner J, Kline CL, Ralff MD, Lev A, Lulla A, Zhou L, Olson GL, Nallaganchu BR, Benes CH, Allen JE, Prabhu VV, Stogniew M, Oster W, El-Deiry WS. Preclinical evaluation of the imipridone family, analogues of clinical stage anti-cancer small molecule ONC201, reveals potent anti-cancer effects of ONC212. Cell Cycle (Georgetown, Tex.). 0. PMID 28489985 DOI: 10.1080/15384101.2017.1325046  0.96
2017 Stein MN, Bertino JR, Kaufman HL, Mayer T, Moss R, Silk A, Chan N, Malhotra J, Rodriguez-Rodriguez L, Aisner J, Aiken RD, Haffty BG, DiPaola RS, Saunders T, Zloza A, ... ... Allen J, et al. First-in-human Clinical Trial of Oral ONC201 in Patients with Refractory Solid Tumors. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 28331050 DOI: 10.1158/1078-0432.CCR-16-2658  0.96
2016 Allen JE, Kline CL, Prabhu VV, Wagner J, Ishizawa J, Madhukar N, Lev A, Baumeister M, Zhou L, Lulla A, Stogniew M, Schalop L, Benes C, Kaufman HL, Pottorf RS, et al. Discovery and clinical introduction of first-in-class imipridone ONC201. Oncotarget. PMID 27602582 DOI: 10.18632/oncotarget.11814  0.96
2016 Kline CL, Van den Heuvel AP, Allen JE, Prabhu VV, Dicker DT, El-Deiry WS. ONC201 kills solid tumor cells by triggering an integrated stress response dependent on ATF4 activation by specific eIF2α kinases. Science Signaling. 9: ra18. PMID 26884600 DOI: 10.1126/scisignal.aac4374  0.88
2016 Ishizawa J, Kojima K, Chachad D, Ruvolo P, Ruvolo V, Jacamo RO, Borthakur G, Mu H, Zeng Z, Tabe Y, Allen JE, Wang Z, Ma W, Lee HC, Orlowski R, et al. ATF4 induction through an atypical integrated stress response to ONC201 triggers p53-independent apoptosis in hematological malignancies. Science Signaling. 9: ra17. PMID 26884599 DOI: 10.1126/scisignal.aac4380  0.88
2016 Allen JE, Crowder RN, El-Deiry WS. Correction: First-In-Class Small Molecule ONC201 Induces DR5 and Cell Death in Tumor but Not Normal Cells to Provide a Wide Therapeutic Index as an Anti-Cancer Agent. Plos One. 11: e0149365. PMID 26863230 DOI: 10.1371/journal.pone.0149365  0.96
2016 Prabhu VV, Hong B, Allen JE, Zhang S, Lulla A, Dicker DT, El-Deiry WS. Small molecule prodigiosin restores p53 tumor suppressor activity in chemoresistant colorectal cancer stem cells via c-Jun-mediated ΔNp73 inhibition and p73 activation. Cancer Research. PMID 26759239 DOI: 10.1158/0008-5472.CAN-14-2430  0.88
2015 Allen JE, Crowder R, El-Deiry WS. First-In-Class Small Molecule ONC201 Induces DR5 and Cell Death in Tumor but Not Normal Cells to Provide a Wide Therapeutic Index as an Anti-Cancer Agent. Plos One. 10: e0143082. PMID 26580220 DOI: 10.1371/journal.pone.0143082  0.88
2015 Talekar MK, Allen JE, Dicker DT, El-Deiry WS. ONC201 induces cell death in pediatric non-Hodgkin's lymphoma cells. Cell Cycle (Georgetown, Tex.). 1-7. PMID 26030065 DOI: 10.1080/15384101.2015.1054086  0.88
2015 Lim B, Allen JE, Prabhu VV, Talekar MK, Finnberg NK, El-Deiry WS. Targeting TRAIL in the treatment of cancer: new developments. Expert Opinion On Therapeutic Targets. 1-15. PMID 26004811 DOI: 10.1517/14728222.2015.1049838  0.88
2015 Allen JE, Krigsfeld G, Patel L, Mayes PA, Dicker DT, Wu GS, El-Deiry WS. Identification of TRAIL-inducing compounds highlights small molecule ONC201/TIC10 as a unique anti-cancer agent that activates the TRAIL pathway. Molecular Cancer. 14: 99. PMID 25927855 DOI: 10.1186/s12943-015-0346-9  0.88
2015 Das A, Kunkel M, Joudeh J, Dicker DT, Scicchitano A, Allen JE, Sarwani N, Yang Z, Kaifi J, Zhu J, Liao J, El-Deiry WS. Clinico-pathological correlation of serial measurement of circulating tumor cells in 24 metastatic colorectal cancer patients receiving chemotherapy reveals interpatient heterogeneity correlated with CEA levels but independent of KRAS and BRAF mutation. Cancer Biology & Therapy. 16: 709-13. PMID 25806877 DOI: 10.1080/15384047.2015.1030555  0.88
2015 Kaifi JT, Kunkel M, Dicker DT, Joude J, Allen JE, Das A, Zhu J, Yang Z, Sarwani NE, Li G, Staveley-O'Carroll KF, El-Deiry WS. Circulating tumor cell levels are elevated in colorectal cancer patients with high tumor burden in the liver. Cancer Biology & Therapy. 16: 690-8. PMID 25785486 DOI: 10.1080/15384047.2015.1026508  0.88
2015 Prabhu VV, Allen JE, Dicker DT, El-Deiry WS. Small-Molecule ONC201/TIC10 Targets Chemotherapy-Resistant Colorectal Cancer Stem-like Cells in an Akt/Foxo3a/TRAIL-Dependent Manner. Cancer Research. 75: 1423-32. PMID 25712124 DOI: 10.1158/0008-5472.CAN-13-3451  0.88
2015 McKee CM, Ding Y, Zhou J, Li C, Huang L, Xin X, He J, Allen JE, El-Deiry WS, Cao Y, Muschel RJ, Xu D. Protease nexin 1 induces apoptosis of prostate tumor cells through inhibition of X-chromosome-linked inhibitor of apoptosis protein. Oncotarget. 6: 3784-96. PMID 25686839  0.88
2015 Allen JE, Prabhu VV, Talekar M, van den Heuvel AP, Lim B, Dicker DT, Fritz JL, Beck A, El-Deiry WS. Genetic and Pharmacological Screens Converge in Identifying FLIP, BCL2, and IAP Proteins as Key Regulators of Sensitivity to the TRAIL-Inducing Anticancer Agent ONC201/TIC10. Cancer Research. 75: 1668-74. PMID 25681273 DOI: 10.1158/0008-5472.CAN-14-2356  0.88
2014 Wagner J, Kline CL, Pottorf RS, Nallaganchu BR, Olson GL, Dicker DT, Allen JE, El-Deiry WS. The angular structure of ONC201, a TRAIL pathway-inducing compound, determines its potent anti-cancer activity. Oncotarget. 5: 12728-37. PMID 25587031  0.88
2014 Patel AS, Allen JE, Dicker DT, Sheehan JM, Glantz MJ, El-Deiry WS. Detection of circulating tumor cells in the cerebrospinal fluid of a patient with a solitary metastasis from breast cancer: A case report. Oncology Letters. 7: 2110-2112. PMID 24932298 DOI: 10.3892/ol.2014.1993  0.88
2014 Allen JE, Patel AS, Prabhu VV, Dicker DT, Sheehan JM, Glantz MJ, El-Deiry WS. COX-2 drives metastatic breast cells from brain lesions into the cerebrospinal fluid and systemic circulation. Cancer Research. 74: 2385-90. PMID 24614081 DOI: 10.1158/0008-5472.CAN-13-2660  0.88
2014 Zhang L, Ren X, Cheng Y, Liu X, Allen JE, Zhang Y, Yuan Y, Huang SY, Yang W, Berg A, Webb BS, Connor J, Liu CG, Lu Z, El-Deiry WS, et al. The NFκB inhibitor, SN50, induces differentiation of glioma stem cells and suppresses their oncogenic phenotype. Cancer Biology & Therapy. 15: 602-11. PMID 24557012 DOI: 10.4161/cbt.28158  0.88
2014 Sinha I, Allen JE, Pinto JT, Sinha R. Methylseleninic acid elevates REDD1 and inhibits prostate cancer cell growth despite AKT activation and mTOR dysregulation in hypoxia. Cancer Medicine. 3: 252-64. PMID 24515947 DOI: 10.1002/cam4.198  0.88
2014 Allen JE, Saroya BS, Kunkel M, Dicker DT, Das A, Peters KL, Joudeh J, Zhu J, El-Deiry WS. Apoptotic circulating tumor cells (CTCs) in the peripheral blood of metastatic colorectal cancer patients are associated with liver metastasis but not CTCs. Oncotarget. 5: 1753-60. PMID 24334302  0.88
2013 Abdulghani J, Allen JE, Dicker DT, Liu YY, Goldenberg D, Smith CD, Humphreys R, El-Deiry WS. Sorafenib sensitizes solid tumors to Apo2L/TRAIL and Apo2L/TRAIL receptor agonist antibodies by the Jak2-Stat3-Mcl1 axis. Plos One. 8: e75414. PMID 24086526 DOI: 10.1371/journal.pone.0075414  0.88
2013 Allen JE, Gallant JN, Dicker DT, Amin S, Irby RB, Sharma AK, El-Deiry WS. The Akt inhibitor ISC-4 synergizes with cetuximab in 5-FU-resistant colon cancer. Plos One. 8: e59380. PMID 23555026 DOI: 10.1371/journal.pone.0059380  0.88
2013 Allen JE, El-Deiry WS. Calcein-effluxing human colon cancer cells are enriched for self-renewal capacity and depend on β-catenin. Oncotarget. 4: 184-91. PMID 23468473  0.88
2013 Allen JE, Krigsfeld G, Mayes PA, Patel L, Dicker DT, Patel AS, Dolloff NG, Messaris E, Scata KA, Wang W, Zhou JY, Wu GS, El-Deiry WS. Dual inactivation of Akt and ERK by TIC10 signals Foxo3a nuclear translocation, TRAIL gene induction, and potent antitumor effects. Science Translational Medicine. 5: 171ra17. PMID 23390247 DOI: 10.1126/scitranslmed.3004828  0.88
2013 Vasekar M, Allen JE, Joudeh J, Claxton D. Emerging molecular therapies for the treatment of acute lymphoblastic leukemia. Advances in Experimental Medicine and Biology. 779: 341-58. PMID 23288648 DOI: 10.1007/978-1-4614-6176-0_16  0.88
2013 Joudeh J, Allen JE, Das A, Prabhu V, Farbaniec M, Adler J, El-Deiry WS. Novel antineoplastics targeting genetic changes in colorectal cancer. Advances in Experimental Medicine and Biology. 779: 1-34. PMID 23288633 DOI: 10.1007/978-1-4614-6176-0_1  0.88
2012 Prabhu VV, Allen JE, Hong B, Zhang S, Cheng H, El-Deiry WS. Therapeutic targeting of the p53 pathway in cancer stem cells. Expert Opinion On Therapeutic Targets. 16: 1161-74. PMID 22998602 DOI: 10.1517/14728222.2012.726985  0.88
2012 Dolloff NG, Allen JE, Dicker DT, Aqui N, Vogl D, Malysz J, Talamo G, El-Deiry WS. Sangivamycin-like molecule 6 exhibits potent anti-multiple myeloma activity through inhibition of cyclin-dependent kinase-9. Molecular Cancer Therapeutics. 11: 2321-30. PMID 22964485 DOI: 10.1158/1535-7163.MCT-12-0578  0.88
2012 Cheng H, Hong B, Zhou L, Allen JE, Tai G, Humphreys R, Dicker DT, Liu YY, El-Deiry WS. Mitomycin C potentiates TRAIL-induced apoptosis through p53-independent upregulation of death receptors: evidence for the role of c-Jun N-terminal kinase activation. Cell Cycle (Georgetown, Tex.). 11: 3312-23. PMID 22895172 DOI: 10.4161/cc.21670  0.88
2012 Allen JE, El-Deiry WS. Regulation of the human TRAIL gene. Cancer Biology & Therapy. 13: 1143-51. PMID 22892844 DOI: 10.4161/cbt.21354  0.88
2012 Allen JE, Ferrini R, Dicker DT, Batzer G, Chen E, Oltean DI, Lin B, Renshaw MW, Kretz-Rommel A, El-Deiry WS. Targeting TRAIL death receptor 4 with trivalent DR4 Atrimer complexes. Molecular Cancer Therapeutics. 11: 2087-95. PMID 22802267 DOI: 10.1158/1535-7163.MCT-12-0366  0.88
2011 Patel AS, Allen JE, Dicker DT, Peters KL, Sheehan JM, Glantz MJ, El-Deiry WS. Identification and enumeration of circulating tumor cells in the cerebrospinal fluid of breast cancer patients with central nervous system metastases. Oncotarget. 2: 752-60. PMID 21987585  0.88
2011 Gallant JN, Allen JE, Smith CD, Dicker DT, Wang W, Dolloff NG, Navaraj A, El-Deiry WS. Quinacrine synergizes with 5-fluorouracil and other therapies in colorectal cancer. Cancer Biology & Therapy. 12: 239-51. PMID 21725213 DOI: 10.4161/cbt.12.3.17034  0.88
2011 Wang W, Gallant JN, Katz SI, Dolloff NG, Smith CD, Abdulghani J, Allen JE, Dicker DT, Hong B, Navaraj A, El-Deiry WS. Quinacrine sensitizes hepatocellular carcinoma cells to TRAIL and chemotherapeutic agents. Cancer Biology & Therapy. 12: 229-38. PMID 21725212 DOI: 10.4161/cbt.12.3.17033  0.88
2011 Allen JE, El-Deiry WS. Oxaliplatin uses JNK to restore TRAIL sensitivity in cancer cells through Bcl-xL inactivation. Gastroenterology. 141: 430-4. PMID 21699898 DOI: 10.1053/j.gastro.2011.06.026  0.88
2011 Faltas B, Zeidan A, Peters K, Das A, Joudeh J, Navaraj A, Dolloff NG, Harvey HA, Jiang Y, Allen JE, Dicker DT, El Deiry WS. Identifying circulating tumor stem cells that matter: the key to prognostication and therapeutic targeting. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 29: 2946-7; author reply. PMID 21690466 DOI: 10.1200/JCO.2011.36.6179  0.88
2011 Mayes PA, Dolloff NG, Daniel CJ, Liu JJ, Hart LS, Kuribayashi K, Allen JE, Jee DI, Dorsey JF, Liu YY, Dicker DT, Brown JM, Furth EE, Klein PS, Sears RC, et al. Overcoming hypoxia-induced apoptotic resistance through combinatorial inhibition of GSK-3β and CDK1. Cancer Research. 71: 5265-75. PMID 21646472 DOI: 10.1158/0008-5472.CAN-11-1383  0.88
2010 Allen JE, El-Deiry WS. Circulating Tumor Cells and Colorectal Cancer. Current Colorectal Cancer Reports. 6: 212-220. PMID 20890370 DOI: 10.1007/s11888-010-0069-7  0.96
2009 Allen JE, Hart LS, Dicker DT, Wang W, El-Deiry WS. Visualization and enrichment of live putative cancer stem cell populations following p53 inactivation or Bax deletion using non-toxic fluorescent dyes. Cancer Biology & Therapy. 8: 2194-205. PMID 19923899  0.96
Show low-probability matches.